|
7th Annual Conference Of The British HIV Association [BHIVA]27 – 29 April 2001, The Hove Centre, Brighton |
[AUTHOR(S):] J Eugen-Olsen1, T Benfield1, J Gerstoft2, K Krogsgaard1, C Pedersen3, N Sidenius4
1 Clinical Research Unit, Hvidovre Hospital, 2 Department of Infectious Diseases, Rigshospitalet, 3 Department of Infectious Diseases, Odense Hospital, Denmark, and 4 Raffaele Scientific Institute, Milan, Italy
BHIVA Conf 2001 Apr 27-29;7:O19
OBJECTIVE: To determine the prognostic value of soluble urokinase receptor (suPAR) and urokinase plasminogen activator (uPA) in a Danish cohort of HIV-infected individuals.
METHODS: suPAR and uPA were measured on frozen serum samples from 133 HIV positive patients enrolled in the Copenhagen AIDS Cohort (CAC). The patients were followed from time of serum sampling (median 1986, range 1984–1994) until May 1996 when the first patient received highly active antiretroviral therapy. Serum suPAR and uPA concentrations were measured by enzyme-linked immunosorbent assay.
RESULTS: All patients had measurable uPA and suPAR. The median suPAR level was 1.75 ng/ml (range 0.5–10.9). Grouped by median suPAR level, the high suPAR patients progressed significantly faster to AIDS (median 4.2 years) and death (median 6.6 years) compared to the low suPAR group (median 8.0 and 8.5 years, respectively, P< 0.05). By Cox regression analysis, both suPAR and CD4 predicted progression to AIDS (P=0.011, HR per ng suPAR increase =1.64 and log10 transformed CD4 counts, P=0.014, HR per log decrease=1.72) and to death (P<0.001, HR=1.42, and P=0.009, HR=1.64, respectively). There was no significant difference in CD4 T cell counts between the high and low suPAR groups (P=0.9, t-test). No significant association between uPA and HIV progression was found.
CONCLUSIONS: suPAR is a strong and independent prognostic factor for HIV disease progression. It is easy to measure and has the potential to be an important tool for determining when to initiate therapy in HIV infected individuals.
PRESENTING AUTHOR: J Eugen-Olsen
010427
O19
Copyright © 2001 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD